勘误：使用3D微流控模型表征单核细胞在T细胞癌症免疫治疗中的作用。
Corrigendum: Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.
作者信息
Lee Sharon Wei Ling, Adriani Giulia, Ceccarello Erica, Pavesi Andrea, Tan Anthony Tanoto, Bertoletti Antonio, Kamm Roger Dale, Wong Siew Cheng
机构信息
BioSystems and Micromechanics IRG, Singapore-MIT Alliance for Research and Technology, Singapore, Singapore.
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
出版信息
Front Immunol. 2018 Jul 24;9:1719. doi: 10.3389/fimmu.2018.01719. eCollection 2018.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2018.00416.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fimmu.2018.00416。]
相似文献
1
Corrigendum: Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.勘误：使用3D微流控模型表征单核细胞在T细胞癌症免疫治疗中的作用。
Front Immunol. 2018 Jul 24;9:1719. doi: 10.3389/fimmu.2018.01719. eCollection 2018.
2
Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.使用三维微流控模型描绘单核细胞在 T 细胞癌症免疫治疗中的作用。
Front Immunol. 2018 Mar 6;9:416. doi: 10.3389/fimmu.2018.00416. eCollection 2018.
3
Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.勘误：舒托西他赛 Zendusortide（TH1902）触发 cGAS/STING 通路并增强抗 PD-L1 免疫介导的肿瘤细胞杀伤。
Front Immunol. 2024 Feb 28;15:1389603. doi: 10.3389/fimmu.2024.1389603. eCollection 2024.
4
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
5
Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.免疫疗法：超越抗PD-1和抗PD-L1疗法
Am Soc Clin Oncol Educ Book. 2016;35:e450-8. doi: 10.1200/EDBK_158712.
6
Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.勘误：一种高效抗VISTA抗体KVA12123——一种新型免疫检查点抑制剂及针对低免疫原性肿瘤的有前景的疗法。
Front Immunol. 2024 Jan 23;15:1365240. doi: 10.3389/fimmu.2024.1365240. eCollection 2024.
7
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.肿瘤微环境调控 PD-1/PD-L1 抗体阻断对小鼠肺肿瘤的敏感性。
Cancer Immunol Res. 2017 Sep;5(9):767-777. doi: 10.1158/2326-6066.CIR-16-0365. Epub 2017 Aug 17.
8
MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.MiR-195/-16家族通过阻断PD-L1免疫检查点激活肿瘤微环境中的T细胞来增强放疗效果。
Cell Physiol Biochem. 2018;48(2):801-814. doi: 10.1159/000491909. Epub 2018 Jul 20.
9
Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy.勘误：癌症进展与免疫治疗中的TNF悖论
Front Immunol. 2019 Oct 22;10:2515. doi: 10.3389/fimmu.2019.02515. eCollection 2019.
10
Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients.勘误：肿瘤细胞上HHLA2和PD-L1的共表达独立预测脊索瘤患者的生存情况。
Front Immunol. 2023 Apr 14;14:1194064. doi: 10.3389/fimmu.2023.1194064. eCollection 2023.
引用本文的文献
1
Modeling Nanocarrier Transport across a 3D In Vitro Human Blood-Brain-Barrier Microvasculature.模拟纳米载体穿越三维体外人血脑屏障微血管系统的运输过程。
Adv Healthc Mater. 2020 Apr;9(7):e1901486. doi: 10.1002/adhm.201901486. Epub 2020 Mar 3.
Zotero 插件